drugset / Trial / NCT00807053

Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

NCT00807053

Phase 2 Completed 480 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to demonstrate the efficacy of ciclesonide HFA, applied as a nasal aerosol once daily, in patients with SAR. The secondary objectives are to evaluate Quality-of-Life and safety.

Timeline

Start
2007-04
Primary completion
2007-06
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ciclesonide Other / unclassified 75 ug Intranasal
Comparator Ciclesonide Other / unclassified 150 ug Intranasal
Comparator Ciclesonide Other / unclassified 300 ug Intranasal